Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

311
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
311
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

265
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
265
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

472
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
472
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.6K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.6K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

826
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
826
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

586
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
586

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent evidence practice gap in antibiotic use for community acquired pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

The ghost of tuberculosis past.

Nature medicine·2026
Same author

Tuberculosis research principles and priorities in children and adolescents: an international consensus statement.

The Lancet. Child & adolescent health·2026
Same author

Molecular diagnostic tests for isoniazid-resistant tuberculosis: a scoping review.

The Lancet. Microbe·2026
Same author

Tuberculosis infection tests for contact screening in Brazil: a cost-effectiveness analysis.

Lancet regional health. Americas·2026
Same author

Whole genome sequencing for Mycobacterium tuberculosis in public health responses: a review of current practice and enablers in select low-incidence jurisdictions.

BMC public health·2026

Related Experiment Video

Updated: Nov 13, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K

Implementing tuberculosis preventive treatment in high-prevalence settings.

Greg J Fox1, Thu Anh Nguyen2, Mikaela Coleman3

  • 1Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; The Woolcock Institute of Medical Research, Glebe, NSW, 2006, Australia.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|March 15, 2021
PubMed
Summary
This summary is machine-generated.

Scaling up tuberculosis preventive treatment (TPT) is crucial for the quarter of the world

Keywords:
Mycobacterium tuberculosislatent tuberculosispatient-centered carepreventive therapyprophylaxis

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.9K

Related Experiment Videos

Last Updated: Nov 13, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

81.4K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.9K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Global Health

Background:

  • Latent tuberculosis infection (LTBI) impacts a quarter of the global population.
  • Effective treatments for LTBI exist, but their widespread implementation is hindered.
  • Scaling up tuberculosis preventive treatment (TPT) is essential in high-prevalence areas.

Purpose of the Study:

  • To outline strategies for enhancing the scale-up of TPT in high-prevalence settings.
  • To emphasize patient-centered approaches in TPT policy development.
  • To highlight the importance of health system strengthening for safe and sustainable TPT delivery.

Main Methods:

  • The study describes strategic approaches for TPT scale-up.
  • It emphasizes integrating patient needs into policy.
  • It addresses health system prerequisites for effective TPT programs.

Main Results:

  • Patient-centered policies are vital for successful TPT scale-up.
  • Addressing health system needs ensures safe, efficient, and sustainable TPT delivery.
  • Further research is needed for localized TPT adaptation and shorter treatment regimens.

Conclusions:

  • Patient-centered strategies and robust health systems are key to scaling up TPT.
  • Tailoring TPT to local contexts and developing shorter treatments are future research priorities.
  • Successful TPT scale-up can significantly benefit individuals at risk of active tuberculosis.